文献-镇静剂||A型毒素的镇静剂效果

古文献-镇痛||A型毒芝用做眉迷走神经节有鉴于此用药多样这两项瘙痒症候群

A型芝用做眉迷走神经节有鉴于此用药多样这两项瘙痒症候群：一项随机试验

Brown故事情节：Brown

本研究旨在有效性芝通过持续升高肌肤温度加长眉迷走神经有鉴于此持续时间的推论。作者进行了一项随机、双盲、折衷试验，研究a型芝用药多样这两项瘙痒症候群症状眉迷走神经节有鉴于此的诊断。

Brown分析方法：Brown

有别于75 IU A型芝（芝四组）和暂时性药（结果表明），对脚部多样这两项瘙痒症候群症状进行眉迷走神经节有鉴于此。

主要结果是1个月初后有鉴于此侧足底与对侧足底的相对湿热叠加。

次要结果是3个月初后的相对湿热叠加以及瘙痒准确度叠加。

Brown结果：Brown

一共48名参与者（N=24/四组）被随机分配。

芝四组的相对温度减少高于结果表明（分列1.0±1.3℃ vs. 0.1±0.8℃；区别：0.9℃[95%CI：0.3～1.5]；P=0.006）。

维持至术后3个月初，为1.1±0.8 ℃ vs.-0.2±1.2 ℃；P=0.009。

此外，与结果表明比起，芝四组在1个月初（分列（-2.2±1.0 vs.-1.0±1.6；P=0.003）和3个月初（分列（-2.0±1.0 vs.-0.6±1.6；P=0.003）时的瘙痒准确度显著降低。

不会与芝注射相关的严重不好政治事件。

Brown结论：Brown

在多样这两项瘙痒症候群症状之中，适用A型芝进行眉迷走神经节有鉴于此可使患足温度升高3个月初，并可减轻瘙痒。

Botulinum Toxin Type A for Lumbar Sympathetic GanglionBlock in Complex Regional Pain Syndrome: A Randomized Trial

Background: The present study was designed totest the hypothesis that botulinum toxin would prolong the duration of a lumbarsympathetic block measured through a sustained increase in skin temperature.The authors performed a randomized, double-blind, controlled trial to investigatethe clinical outcome of botulinum toxin type A for lumbar sympathetic ganglionblock in patients with complex regional pain syndrome.

Methods: Lumbar sympathetic ganglion block wasconducted in patients with lower-extremity complex regional pain syndrome using75 IU of botulinum toxin type A (botulinum toxin group) and local anesthetic(control group). The primary outcome was the change in the relative temperaturedifference on the blocked sole compared with the contralateral sole at 1postoperative month. The secondary outcomes were the 3-month changes inrelative temperature differences, as well as the pain intensity changes.

Results: A total of 48 participants (N = 24/group)were randomly assigned. The change in relative temperature increase was higherin the botulinum toxin group than in the control group (1.0°C ± 1.3 vs. 0.1°C ±0.8, respectively; difference: 0.9°C [95% CI, 0.3 to 1.5]; P = 0.006), whichwas maintained at 3 months (1.1°C ± 0.8 vs. -0.2°C ± 1.2, respectively; P =0.009). Moreover, pain intensity was greatly reduced in the botulinum toxingroup compared with the control group at 1 month (-2.2 ± 1.0 vs. -1.0 ± 1.6,respectively; P = 0.003) and 3 months (-2.0 ± 1.0 vs. -0.6 ± 1.6, respectively;P = 0.003). There were no severe adverse events pertinent to botulinum toxininjection.

Conclusions: In patients with complex regionalpain syndrome, lumbar sympathetic ganglion block using botulinum toxin type Aincreased the temperature of the affected foot for 3 months and also reducedthe pain.